Notes from the laboratory as the work moves. Science only. No promotions, no discounts.
Read the notes →OF·27 stabilises FGF·2 and FGF·7 in a plant-derived oleosome carrier, a nightly scalp protocol whose result was reported in a randomised, blind, placebo-controlled study.
The Follicular Serum earned its result on its own. Twelve weeks of nightly use, measured against placebo in an independent clinical study. Its oleosome carrier already takes the growth factors to the follicle.
The follicle grows out of its environment. Inflammation, excess sebum, and oxidative stress degrade that environment, so even a perfectly delivered signal meets a follicle in poor condition to act on it.
That is why we built Phase 1. Scalp Reset reduces buildup, excess sebum, and irritation once or twice a week, so the follicle sits in an environment ready to respond, and the nightly signal of Phase 2 converts into growth at its full potential.
A rinse-off exfoliating treatment, applied to a dry scalp and rinsed after 3–5 minutes. Reduces buildup, calms irritation, restores balance: the environment work. One bottle covers all twelve weeks.
One pump massaged into the scalp before bed and left on overnight. FGF·2 and FGF·7, carried to the follicle by the oleosome fusion. Six weeks per bottle; the studied course is two.
A prepared scalp responds better. Delivery is already solved: the oleosome carrier brings the growth factors to the follicle. Phase 1's job is the environment, reducing inflammation, excess sebum, and oxidation so the follicle can act on the signal.
The course matches the study. The published +33.5% hair density was measured after twelve weeks of nightly use. One Follicular bottle covers six weeks; the course is two bottles.
Maintenance, one bottle every six weeks. Density holds with continued use and returns toward baseline if you stop. The written protocol, included with every order, covers both phases step by step.
Before the stimulant goes on, OF·27 prepares the environment it works in: this treatment reduces buildup, excess oil, and irritation, so the follicle is in the best condition to respond to the nightly signal.
A rinse-off exfoliating treatment, once or twice a week. It reduces the inflammation, excess sebum, and buildup that leave a follicle in poor condition to respond, so Phase 2's nightly signal converts into growth at full potential. One bottle covers the full twelve-week course.
One bottle covers six weeks; the studied course is twelve. The shipment arrives sealed; the protocol begins on the day it is opened.
The stimulant itself: FGF·2 and FGF·7, one pump massaged into the scalp nightly. Six weeks per bottle, two bottles for the course the study measured. Everything else, dosing, storage, technique, is in the written protocol.
OF·27 is formulated with FGF·2 and FGF·7, two fibroblast growth factors stabilised as oleosome fusions so they reach the follicle intact, the part conventional topical proteins fail at.
An independent study on the active. Report open: Abich REL/0504/2026.
Not a leave-on serum. A twelve-week course of a characterised oleosome-protein fusion, with a defined endpoint.
Keeping two proteins active in a topical is the hard part, named and explained, not marketed.
The follicle does two things during a healthy growth cycle: it decides when to begin growing, and it builds the hair shaft once it has begun.1 OF·27 supplies one recombinant signal for each step, stabilised by an oleosome.
A 17 kDa heparin-binding signalling protein. It binds the FGF Receptor on the surface of the dermal papilla, the cell cluster at the base of the follicle that decides when a hair transitions from rest (telogen) to active growth (anagen).2 FGF·2 is the start-work order: without sufficient signal, the transition is delayed and shedding outpaces regrowth.
A keratinocyte-specific growth factor. It binds the FGF Receptor on the keratinocytes that physically construct the hair shaft, driving their renewal and differentiation.3 If FGF·2 is the start-work order, FGF·7 is the construction instruction: it tells the cells what to assemble once the follicle has committed to growth.
The plant's natural energy-storage organelle: a lipid core surrounded by a single phospholipid layer with oleosin proteins embedded in it. Each growth factor is expressed in the seed as an oleosin fusion; the lipid envelope assembles around the protein during seed development.4 The envelope shields the active protein from the aqueous denaturation that defeats conventional topical growth-factor formulations.5
A free growth factor loses activity on the way to the follicle, denaturing in solution. Carried inside the oleosome, OF·27's signal holds at the concentration declared on the carton, all the way to the follicle.
The full report was issued 02 March 2026 by Abich S.r.l., an ISO 9001 and ISO 13485 (quality and clinical-testing certifications) certified clinical centre in Italy.
The protocol was randomised, single-blind, placebo-controlled. Volunteers did not know which formulation they were applying.
Mean visible hairs per cm², measured by C-CUBE® phototrichogram (a scalp-imaging device that counts hairs) at T0, T28, T56, T84.
Proportion of follicles in active growth (anagen) versus resting (telogen). A higher ratio means a greater share of follicles producing hair.
Mean diameter of visible hair shafts in micrometres (µm), measured by calibrated optical analysis.
Hydration measured by Corneometer® and transepidermal water loss by Nano-Tewameter®, indicators of barrier integrity on the scalp.
The study reports a group-mean response. The cohort had a mean density increase of +33.5%; the distribution spans non-responders to high-responders. Individual response will not match the mean.
We are not making a comparative claim against minoxidil, finasteride, or any other named treatment. OF·27 was tested against its own vehicle placebo.
40 healthy female volunteers with telogen effluvium (a common, temporary form of hair shedding) were randomised between active and placebo serum. Investigators measured hair density, anagen/telogen ratio, shaft thickness, scalp hydration and TEWL (water loss) by C-CUBE® Pixience and Courage-Khazaka instruments at four timepoints over eighty-four days. Volunteers were blinded to the formulation.
Before the clinical study, the growth-factor complex was tested on human dermal papilla cells, the cluster at the base of the follicle that governs the growth cycle. Gene expression was read after two days against an untreated control.
The marker of actively dividing cells. The clearest signal in the panel: dermal papilla cells entered an active growth state.
A marker of dermal-papilla inductivity: the papilla's capacity to instruct a follicle to grow.
A standard readout of dermal-papilla activity and the follicle's growth-phase competence.
Angiogenic (VEGFA) and growth (FGF2) signalling, each roughly doubled at the higher dose.
Mechanistic, cell-level evidence that the complex engages the hair-growth programme in the dermal papilla. It explains why a density change is biologically plausible; it does not measure one.
Not a clinical result, and not a substitute for one. Hair density on people is reported only in the Results section, from the randomised, placebo-controlled study. Fold-changes are gene expression, not hairs.
If your question is not answered here, we are reachable at contact@of27bioscience.com. We answer technical questions in plain prose.
Two recombinant fibroblast growth factors stabilised in a plant-derived oleosome carrier. The formulation table is published in full; see Note 09 · The study.
No. OF·27 is a topical cosmetic. It has been assessed in an independent clinical study, but it is not a drug and is not intended to treat or prevent any disease, and nothing here is a medical claim.
A randomised, single-blind, placebo-controlled study, conducted by Abich S.r.l. in Italy between 17 November 2025 and 13 February 2026. Forty healthy female volunteers with telogen effluvium (a common, temporary form of hair shedding) were split equally between active and placebo arms. Volunteers were not told which formulation they were applying.
The active group's mean hair density increased by +33.5% vs. baseline (p<0.0001, statistically significant) at week 12. The placebo group increased by +7.2% (not statistically significant).
ABICH REL/0504/2026 · ISSUED 02/03/2026 · ISO 9001 / ISO 13485 (quality and clinical-testing certifications)
Four parameters at four timepoints (T0, T28, T56, T84):
Hair density (visible hairs per cm²) by C-CUBE Pixience phototrichogram (a scalp-imaging device that counts hairs). Anagen/telogen ratio (proportion of follicles in active growth) by the same device. Hair shaft thickness in micrometres by calibrated optical analysis. Scalp hydration by Corneometer® and transepidermal water loss by Nano-Tewameter®.
Active group changes at week 12: density +33.5%, anagen/telogen +17.0%, shaft thickness +10.6%, hydration +22.2%, TEWL (water loss) −27.2%. The placebo group did not reach statistical significance on density or anagen ratio.
The study reports a group-mean response of +33.5%. The individual distribution spans non-responders to high-responders. Note 09 · The study lists the inclusion criteria (healthy female volunteers experiencing telogen effluvium) so a reader can compare her situation to the cohort.
We do not extrapolate from a group mean to a personal prediction.
Minoxidil is a small-molecule vasodilator applied topically. Finasteride is a 5-alpha reductase inhibitor (typically oral, prescription). OF·27 is neither. It is a topical containing recombinant growth factor proteins that signal to follicle cells through a different mechanism.
The three are not direct substitutes. The study does not make a comparative claim against either.
A plant-derived lipid body. Certain oilseeds naturally produce them as energy storage. When a growth factor protein is expressed in the seed alongside an oleosome, the two fuse during seed development.
The fused complex survives extraction, formulation, and the journey from bottle to scalp at concentrations the formulation declares. Proteins denature in solution; the oleosome lipid envelope stabilises them.
One pump applied nightly, directly to the scalp (not the lengths), focusing on areas where hair appears thinner. Each pump delivers roughly 1 mL (about 1 cc), so one 50 mL airless pump bottle covers six weeks of nightly use. Massage thoroughly into the scalp for at least thirty seconds, then leave on overnight; do not rinse. The airless dispenser keeps each dose isolated from air until application.
The published twelve-week primary endpoint is reached by completing two consecutive bottles, twelve weeks of nightly use.
We recommend refrigerating OF·27 at 2 to 8 °C. The actives are biologics, and cold storage best preserves their activity across the course, so it is the conservative choice rather than a strict requirement. The formulation tolerates room temperature without harm, whether during application or in transit; where convenient, return the bottle to the fridge after use.
Do not freeze. Freezing ruptures the oleosome carrier and irreversibly denatures the proteins. A bottle that has frozen should not be used.
FGF·2 and FGF·7 have been studied in dermatology and wound healing for decades; recombinant forms are present in approved wound-care products. The Abich study recorded the formulation against vehicle placebo over twelve weeks under medical supervision.
Volunteers were screened for irritated skin, active dermatological pathology, and recent topical medication. No serious adverse events were reported during the trial.
The Abich study cohort was all-female (n=40, 40 participants), recruited specifically for telogen effluvium. We do not yet have male-cohort data and will not extrapolate. A separate male-cohort study is in planning.
In the United States, under ISO 22716, the cosmetics manufacturing standard. Each bottle carries a batch identifier, manufacturing date, and expiry.
Yes. Apply to a clean, towel-dried scalp before any other leave-in product. The formulation absorbs in under sixty seconds and does not interact with shampoos, conditioners, or styling products.
If you are using a prescribed topical (minoxidil, prescription steroids), discuss the addition with your dermatologist.
No. The clinical study cohort was human. Pre-clinical work used in vitro hair follicle organ culture, not animal models.
The study is published in full and peer-reviewed. Read it in the peer-reviewed journal International Journal of Clinical & Experimental Dermatology(IJCED) ⇗. It sets out the protocol, the cohort criteria, the endpoint definitions, the results tables, the statistical significance summaries, and the adverse-event record. For a plain-language walkthrough, see Note 09 · The study.
Funding disclosure: this efficacy study was published by Core Biogenesis, the supplier of the active ingredient.
OF·27 is an independent hair-density research program. It is built on two fibroblast growth factors, FGF·2 and FGF·7, stabilised as oleosome fusions and formulated into a twelve-week scalp protocol. We report the evidence rather than describe a benefit.
The program operates like a publication. The methodology document — Note 09 · The study — is the primary asset; the product is what carries the protocol forward. We publish, we don't promise. For a methodological question, OF·27 is reachable at contact@of27bioscience.com, answered in plain prose.
Growth factors are signaling proteins. In topical application their challenge has always been the same: proteins denature in aqueous solution. The active concentration on the scalp, twenty minutes after application, is rarely the concentration that was formulated.
The active in OF·27 is supplied by Core Biogenesis, a French biotechnology company, which solved this in the seed. Its platform expresses each growth factor inside Camelina sativa (a flaxseed relative) alongside an oleosome, a lipid body the plant already produces for energy storage. The two fuse during seed development, and the fused complex survives extraction, formulation, and the journey from bottle to scalp at the concentrations the formulation declares.
Every external claim is cited. The clinical study on the active is independent, its methodology is open, and the report identifier is reservable for citation in other work.
The voice is sentence case. The headlines do not use comparative adjectives. The bottle carries a batch identifier. The visual register is that of a research program: clinical, institutional, documentary.
The works below substantiate the mechanistic and biological claims made on this page: the roles of FGF·2 and FGF·7 in the hair follicle, the structure of the growth cycle, and the principle of carrying proteins on plant oil bodies. They do not report on OF·27 itself — the clinical outcomes shown above are from the Abich study (REL/0504/2026), cited in full in the Results section.